Weight Loss and Weight Regain in Usual Clinical Practice: Results From the TARGET-NASH Observational Cohort
Miguel H Malespin, Alfred Sidney Barritt 4th, Stephanie E Watkins, Cheryl Schoen, Monica A Tincopa, Karen D Corbin, Andrea R Mospan, Breda Munoz, Huy N Trinh, L Michael Weiss, K Rajender Reddy, Rohit Loomba, Nyingi Kemmer, Anna S Lok, Miguel H Malespin, Alfred Sidney Barritt 4th, Stephanie E Watkins, Cheryl Schoen, Monica A Tincopa, Karen D Corbin, Andrea R Mospan, Breda Munoz, Huy N Trinh, L Michael Weiss, K Rajender Reddy, Rohit Loomba, Nyingi Kemmer, Anna S Lok
Abstract
First-line treatment for nonalcoholic fatty liver disease (NAFLD) focuses on weight loss through lifestyle modifications.1,2 Weight loss ≥5% results in reduction of steatosis and weight loss ≥10% has been associated with improvement in hepatic inflammation and fibrosis.3 The incidence and sustainability of weight loss among patients with NAFLD were estimated and associating factors identified.
Trial registration: ClinicalTrials.gov NCT02815891.
Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.
Source: PubMed